Which one is better, cabergoline or bromocriptine?

Cabergoline (Cabergoline) and bromocriptine (Bromocriptine) are common dopamine receptor agonists in the treatment of hyperprolactinemia, pituitary prolactinoma, and Parkinson's disease. The two drugs are similar in their mechanism of action. Both inhibit the secretion of prolactin from the anterior pituitary gland by activating dopamine D2 receptors. However, there are obvious differences in pharmacokinetics, efficacy, tolerance and ease of use. So, which drug is more worth choosing? This article will conduct a comparative analysis from multiple dimensions to help patients make more scientific choices.

First of all, cabergoline is generally considered to be a more advantageous drug in terms of efficacy and duration of effect. Studies have shown that cabergoline is more effective than bromocriptine in treating hyperprolactinemia, returning prolactin levels to normal in a shorter period of time and significantly reducing the size of pituitary tumors. More importantly, cabergoline has a longer duration of effect, and usually only needs to be taken 1~2 times a week to control the condition; while bromocriptine needs to be taken daily2~3 times, and some patients even need to take it 4 or more times. The frequency of taking medicine is high and the compliance is poor. Therefore, cabergoline has more advantages for patients pursuing long-term disease control and medication convenience.

Secondly, in terms of the incidence and tolerability of side effects, cabergoline shows better safety. The more common adverse reactions of bromocriptine include nausea, vomiting, hypotension, dizziness, headache and fatigue, and many patients are unable to tolerate these symptoms in the early stages, often leading to early discontinuation or poor compliance. Cabergoline has been clinically proven to have fewer side effects and a more stable onset of action. Even if mild gastrointestinal reactions occur, they are usually relieved after taking the drug for a period of time. Some studies have pointed out that cabergoline has a lower probability of causing drug resistance during long-term treatment, which is one of the advantages that bromocriptine cannot match.

Third, there are slight differences between the two in terms of applicability to special groups. As a drug with a longer history, bromocriptine has already received relatively sufficient data support for its use during pregnancy. Especially when hyperprolactinemia is discovered in early pregnancy, doctors are more inclined to use bromocriptine to ensure the safety of the fetus. Although cabergoline is also recommended by some guidelines for use by women during childbearing years, it still needs to be used under strict supervision by a doctor. Cabergoline is better tolerated and adhered to in the nonpregnant population, making it more suitable for the vast majority of patients with chronic hyperprolactinemia or pituitary tumors.

Fourth, from the perspective of economic cost, the price of cabergoline is generally higher than that of bromocriptine. Especially the original version of cabergoline, the price ranges from a few hundred to thousands of yuan; as an old drug, bromocriptine already has a variety of generic drugs to choose from, and the price is more affordable. However, in many countries and regions, cabergoline has been included in the medical insurance catalog, and the proportion of patients paying out of pocket has been significantly reduced. Moreover, because cabergoline requires fewer doses and has a more stable effect, it indirectly saves the cost of follow-up visits and dosage adjustments, and it also has certain economic advantages in the long run.

In summary, if patients pursue better efficacy, fewer side effects, and more convenient medication, then cabergoline is undoubtedly a more worthy drug of choice, especially for patients who are intolerant to bromocriptine, require long-term treatment, or want to shrink pituitary tumors. For patients with limited financial conditions or who need more safety data to support its use during pregnancy, bromocriptine is still a reliable treatment option. The final drug selection should be comprehensively judged based on the patient's own situation, doctor's advice and actual drug response to achieve a balance between the best treatment effect and quality of life.

Reference materials:https://my.clevelandclinic.org/health/drugs/20863-cabergoline-tablets